The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Search
2.2. Selection Criteria
2.3. Data Extraction and Quality Assessment
2.4. Statistical Analysis
Author | Country | Study Type | NOS | Time of Study | No. | Anatomical Site | Histology (%) | Grade H/I/L (%) | Surgery Type (%) | RT Technique | Median Total Dose (Gy) (Range) | RT Target | Post-op CCRT (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yan, 2023 [17] | China | S/R | 5 | 2004–2020 | 418 | Major salivary glands | All subtypes | 22/0/78 | - | 3D, IMRT | - | - | 11 |
Park, 2023 [18] | Korea | M/R | 6 | 2004–2019 | 118 | Parotid gland | All subtypes | 42/8/50 | P (83)/P + LND (17) | 3D, IMRT | 63 (54–78.75) | TB (71)/TB + NI (29) | 2 |
Duru Birgi, 2023 [19] | Turkey | S/R | 6 | 2013–2018 | 18 | Parotid gland | All subtypes | - | P (67)/ P + LND (33) | IMRT | 66 (60–70) | TB (39)/TB + NI (61) | 17 |
Hsieh_A, 2023 [20] | Taiwan | M/R | 7 | 2000–2015 | 263 | All salivary glands | All subtypes | 72/28 a | P ± LND | 3D, IMRT | 62 ± 9 b | TB + NI | 0 |
Hsieh_B, 2023 [20] | Taiwan | M/R | 7 | 2000–2015 | 148 | All salivary glands | All subtypes | 88/12 a | P ± LND | 3D, IMRT | 65 ± 8 b | TB + NI | 100 |
Zang, 2022 [21] | China | S/R | 5 | 2009–2016 | 60 | Major salivary glands | All subtypes | - | P (30)/ P + LND (70) | IMRT | 63 (60–68) | TB (7)/TB + NI (93) | 7 |
Franco, 2021 [22] | USA | S/R | 5 | 2008–2020 | 72 | All salivary glands | All subtypes excluding ACC | - | - | IMRT | - | - | 42 |
Dou, 2019 [23] | China | S/P2 | 6 | 2016–2018 | 52 | All salivary glands | Intermediate or high-grade histology | - | - | IMRT | NR (60–66) | - | 100 |
Nutting_A, 2018 [24] | UK | M/P3 | 7 | 2008–2013 | 54 | Parotid gland | All subtypes | 43/17/30 | - | 3D | 65 (58–65) | TB+/−NI | 0 |
Nutting_B, 2018 [24] | UK | M/P3 | 7 | 2008–2013 | 56 | Parotid gland | All subtypes | 32/20/38 | - | IMRT | 65 (60–65) | TB+/−NI | 0 |
Nishikado, 2018 [25] | Japan | S/R | 4 | 1999–2007 | 58 | Parotid gland | All subtypes | - | - | - | 60 c (NR) | - | 0 |
Li, 2018 [26] | China | M/P2 | 6 | 2013–2016 | 20 | All salivary glands | Intermediate/high-grade histology | 40/60/0 | - | 3D, IMRT | 66 (NR) | TB + NI | 100 |
Gebhardt, 2018 [27] | USA | S/R | 6 | 2002–2015 | 128 | All salivary glands | All subtypes | 45/23/24 | P (47)/ P + LND (53) | IMRT | 66 (45–70.2) | TB (17)/TB + NI (83) | 22 |
Boon, 2018 [28] | Netherland | M/R | 5 | 2000–2016 | 15 | All salivary glands | Secretory carcinoma with ETV6-NTRK3 fusion gene | 0/0/100 | P ± LND | - | 66 (60–66) | TB (27)/TB + NI (27) | 0 |
Zhang, 2017 [29] | China | S/R | 5 | 2008–2014 | 30 | Parotid gland | All subtypes | - | P (33)/ P + LND (67) | 2D, IMRT | NR (60–70) | TB+/−NI | 0 |
Gutschenritter, 2017 [30] | USA | S/R | 4 | 2002–2014 | 78 | All salivary glands | All subtypes | - | P ± LND | 3D, IMRT | NR (50–66) | - | 0 |
Sayan, 2016 [31] | USA | S/R | 5 | 2006–2015 | 20 | Major salivary glands | All subtypes | - | P (60)/ P + LND (40) | 3D, IMRT | 60 (NR) | TB (55)/TB + NI (45) | 0 |
Mifsud_A, 2016 [32] | USA | S/R | 6 | 1998–2013 | 103 | All salivary glands | All subtypes | 37/26/29 | - | - | 64 (45–72) d | - | 0 |
Mifsud_B, 2016 [32] | USA | S/R | 6 | 1998–2013 | 37 | All salivary glands | All subtypes | 73/5/11 | - | - | 64 (45–72) d | - | 100 |
Hosni, 2016 [33] | Canada | S/R | 7 | 2000–2012 | 304 | Major salivary glands | All subtypes | 41/21/38 | P (49)/ P + LND (51) | 3D, IMRT | 66 (46–74) | TB (62)/TB + NI (38) | 3 |
Haderlein, 2016 [34] | Germany | S/R | 5 | 2000–2014 | 63 | All salivary glands | All subtypes | 64/19/14 | P (6)/ P + LND (94) | 3D, IMRT | 64 (45–74) | TB (25)/TB + NI (75) | 46 |
Kaur, 2014 [35] | India | S/R | 5 | 1998–2008 | 39 | Major salivary glands | All subtypes | - | P ± LND | 2D, 3D | 60 (24–64) | - | 0 |
Tam, 2013 [36] | USA | S/R | 6 | 1990–2011 | 200 | Major salivary glands | All subtypes | - | P (64)/ P + LND (36) | 2D, 3D, IMRT | 63 (60–66) | TB+/−NI | 10 |
Chung, 2013 [37] | USA | S/R | 5 | 1998–2011 | 37 | Major salivary glands | All subtypes excluding ACC | - | P (65)/ P + LND (35) | 3D, IMRT | 60 (46–70) | TB+/−NI | 24 |
Kim, 2012 [38] | Korea | S/R | 5 | 1998–2010 | 35 | Major salivary glands | Salivary duct carcinoma | 100/0/0 | P (11)/P + LND (89) | - | 59.4 (50.4–71.4) | TB + NI (100) | 9 |
Al-Mamgani, 2012 [39] | Netherlands | S/R | 6 | 1995–2010 | 186 | Parotid gland | All subtypes | 40/10/41 | P (77)/ P + LND (23) | 2D,3D, IMRT | 66 (54–70) | TB+/−NI | 2 |
Pederson, 2011 [40] | USA | M/R | 5 | 1991–2007 | 24 | All salivary glands | All subtypes | 79/0/21 | P (12)/ P + LND (88) | 2D,3D, IMRT | 65 (55–68) | - | 100 |
Noh, 2010 [41] | Korea | S/R | 5 | 1995–2006 | 75 | Major salivary glands | All subtypes | 83/0/17 | P (64)/ P + LND (36) | 3D | 56 (54–70) | TB (73)/P + NI (27) | 0 |
Chen, 2007 [42] | USA | S/R | 7 | 1960–2004 | 251 | All salivary glands | All subtypes | - | - | 2D,3D, IMRT | 63 (45–72) | TB (48)/TB + NI (52) | 4 |
3. Results
3.1. Search Result
3.2. Selected Studies’ Characteristics
3.3. Survivals
3.4. Late Toxicities
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Skalova, A.; Hyrcza, M.D.; Leivo, I. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands. Head Neck Pathol. 2022, 16, 40–53. [Google Scholar] [CrossRef] [PubMed]
- Young, A.; Okuyemi, O.T. Malignant Salivary Gland Tumors. In Statpearls; StatPearls Publishing: Treasure Island, FL, USA, 2023. [Google Scholar]
- Dos Santos, E.S.; Rodrigues-Fernandes, C.I.; Speight, P.M.; Khurram, S.A.; Alsanie, I.; Normando, A.G.C.; Prado-Ribeiro, A.C.; Brandao, T.B.; Kowalski, L.P.; Guerra, E.N.S.; et al. Impact of Tumor Site on the Prognosis of Salivary Gland Neoplasms: A Systematic Review and Meta-Analysis. Crit. Rev. Oncol. Hematol. 2021, 162, 103352. [Google Scholar] [CrossRef] [PubMed]
- Thomson, D.J.; Slevin, N.J.; Mendenhall, W.M. Indications for Salivary Gland Radiotherapy. Adv. Otorhinolaryngol. 2016, 78, 141–147. [Google Scholar] [PubMed]
- Spiro, R.H. Management of Malignant Tumors of the Salivary Glands. Oncology 1998, 12, 671–680, Discussion 683. [Google Scholar] [PubMed]
- Geiger, J.L.; Ismaila, N.; Beadle, B.; Caudell, J.J.; Chau, N.; Deschler, D.; Glastonbury, C.; Kaufman, M.; Lamarre, E.; Lau, H.Y.; et al. Management of Salivary Gland Malignancy: Asco Guideline. J. Clin. Oncol. 2021, 39, 1909–1941. [Google Scholar] [CrossRef] [PubMed]
- van Herpen, C.; Poorten, V.V.; Skalova, A.; Terhaard, C.; Maroldi, R.; van Engen, A.; Baujat, B.; Locati, L.D.; Jensen, A.D.; Smeele, L.; et al. Salivary Gland Cancer: Esmo-European Reference Network on Rare Adult Solid Cancers (Euracan) Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up. ESMO Open 2022, 7, 100602. [Google Scholar] [CrossRef] [PubMed]
- Thariat, J.; Ferrand, F.R.; Fakhry, N.; Even, C.; Vergez, S.; Chabrillac, E.; Sarradin, V.; Digue, L.; Troussier, I.; Bensadoun, R.J. Radiotherapy for Salivary Gland Cancer: Refcor Recommendations by the Formal Consensus Method. Eur. Ann. Otorhinolaryngol. Head Neck Dis. 2023, 23, S1879–S7296. [Google Scholar] [CrossRef]
- NCCN. Clinical Practice Guidelines in Oncology: Head and Neck Cancers Version 2. 2024. Available online: https://www.nccn.org/professionals/physician_Gls/Pdf/Head-and-Neck.Pdf (accessed on 21 June 2024).
- Locati, L.D.; Ferrarotto, R.; Licitra, L.; Benazzo, M.; Preda, L.; Farina, D.; Gatta, G.; Lombardi, D.; Nicolai, P.; Poorten, V.V.; et al. Current Management and Future Challenges in Salivary Glands Cancer. Front. Oncol. 2023, 13, 1264287. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The Prisma 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef]
- Pieper, D.; Rombey, T. Where to Prospectively Register a Systematic Review. Syst. Rev. 2022, 11, 8. [Google Scholar] [CrossRef]
- Andersen, M.; Fonnes, S.; Andresen, K.; Rosenberg, J. Most Published Meta-Analyses Were Made Available within Two Years of Protocol Registration. Eur. J. Integr. Med. 2021, 44, 101342. [Google Scholar] [CrossRef]
- Stang, A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. Eur. J. Epidemiol. 2010, 25, 603–605. [Google Scholar] [CrossRef] [PubMed]
- Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring Inconsistency in Meta-Analyses. BMJ 2003, 327, 557–560. [Google Scholar] [CrossRef]
- Raudenbush, S.W. Analyzing Effect Sizes: Random-Effects Models. In Handbook of Research Synthesis and Meta-Analysis, 2nd ed.; Russell Sage Foundation: New York, NY, USA, 2009; pp. 295–315. [Google Scholar]
- Yan, W.; Ou, X.; Shen, C.; Hu, C. A Nomogram Involving Immune-Inflammation Index for Predicting Distant Metastasis-Free Survival of Major Salivary Gland Carcinoma Following Postoperative Radiotherapy. Cancer Med. 2023, 12, 2772–2781. [Google Scholar] [CrossRef] [PubMed]
- Park, J.B.; Wu, H.G.; Kim, J.H.; Lee, J.H.; Ahn, S.H.; Chung, E.J.; Eom, K.Y.; Jeong, W.J.; Kwon, T.K.; Kim, S.; et al. Adjuvant Radiotherapy in Node-Negative Salivary Malignancies of the Parotid Gland: A Multi-Institutional Analysis. Radiother. Oncol. 2023, 183, 109554. [Google Scholar] [CrossRef]
- Duru Birgi, S.; Akyurek, S.; Birgi, E.; Arslan, Y.; Gumustepe, E.; Bakirarar, B.; Gokce, S.C. Dosimetric Investigation of Radiation-Induced Trigeminal Nerve Toxicity in Parotid Tumor Patients. Head Neck 2023, 45, 2907–2914. [Google Scholar] [CrossRef] [PubMed]
- Hsieh, R.C.; Chou, Y.C.; Hung, C.Y.; Lee, L.Y.; Venkatesulu, B.P.; Huang, S.F.; Liao, C.T.; Cheng, N.M.; Wang, H.M.; Wu, C.E.; et al. A Multicenter Retrospective Analysis of Patients with Salivary Gland Carcinoma Treated with Postoperative Radiotherapy Alone or Chemoradiotherapy. Radiother. Oncol. 2023, 188, 109891. [Google Scholar] [CrossRef]
- Zang, S.; Chen, M.; Huang, H.; Zhu, X.; Li, X.; Yan, D.; Yan, S. Oncological Outcomes of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: A Retrospective Cohort Study. Quant. Imaging Med. Surg. 2022, 12, 2841–2854. [Google Scholar] [CrossRef] [PubMed]
- Franco, I.I.; Shin, K.Y.; Jo, V.; Hanna, G.J.; Schoenfeld, J.D.; Tishler, R.B.; Milligan, M.G.; Rettig, E.M.; Margalit, D.N. Identification of Salivary Gland Tumors (Sgt) at Risk for Local or Distant Recurrence after Postoperative Radiation Therapy (Port) with or without Systemic Therapy (St) Using Clinical Risk Grouping. Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, e414. [Google Scholar] [CrossRef]
- Dou, S.; Wang, X.; Li, R.; Wu, S.; Ruan, M.; Yang, W.; Zhu, G. Prospective Phase Ii Study of Concurrent Chemoradiotherapy in High-Risk Malignant Salivary Gland Tumors. Int. J. Radiat. Oncol. Biol. Phys. 2019, 105, S214. [Google Scholar] [CrossRef]
- Nutting, C.M.; Morden, J.P.; Beasley, M.; Bhide, S.; Cook, A.; De Winton, E.; Emson, M.; Evans, M.; Fresco, L.; Gollins, S.; et al. Results of a Multicentre Randomised Controlled Trial of Cochlear-Sparing Intensity-Modulated Radiotherapy Versus Conventional Radiotherapy in Patients with Parotid Cancer (Costar; Cruk/08/004). Eur. J. Cancer 2018, 103, 249–258. [Google Scholar] [CrossRef] [PubMed]
- Nishikado, A.; Kawata, R.; Haginomori, S.I.; Terada, T.; Higashino, M.; Kurisu, Y.; Hirose, Y. A Clinicopathological Study of Parotid Carcinoma: 18-Year Review of 171 Patients at a Single Institution. Int. J. Clin. Oncol. 2018, 23, 615–624. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Dou, S.; Ruan, M.; Zhang, C.; Zhu, G. A Feasibility and Safety Study of Concurrent Chemotherapy Based on Genetic Testing in Patients with High-Risk Salivary Gland Tumors: Preliminary Results. Medicine 2018, 97, e0564. [Google Scholar] [CrossRef] [PubMed]
- Gebhardt, B.J.; Ohr, J.P.; Ferris, R.L.; Duvvuri, U.; Kim, S.; Johnson, J.T.; Heron, D.E.; Clump, D.A., 2nd. Concurrent Chemoradiotherapy in the Adjuvant Treatment of High-Risk Primary Salivary Gland Malignancies. Am. J. Clin. Oncol. 2018, 41, 888–893. [Google Scholar] [CrossRef] [PubMed]
- Boon, E.; Valstar, M.H.; van der Graaf, W.T.A.; Bloemena, E.; Willems, S.M.; Meeuwis, C.A.; Slootweg, P.J.; Smit, L.A.; Merkx, M.A.W.; Takes, R.P.; et al. Clinicopathological Characteristics and Outcome of 31 Patients with Etv6-Ntrk3 Fusion Gene Confirmed (Mammary Analogue) Secretory Carcinoma of Salivary Glands. Oral. Oncol. 2018, 82, 29–33. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Zeng, X.; Lan, X.; Huang, J.; Luo, K.; Tian, K.; Wu, X.; Xiao, F.; Li, S. Reoperation Following the Use of Non-Standardized Procedures for Malignant Parotid Tumors. Oncol. Lett. 2017, 14, 6701–6707. [Google Scholar] [CrossRef]
- Gutschenritter, T.; Machiorlatti, M.; Vesely, S.; Ahmad, B.; Razaq, W.; Razaq, M. Outcomes and Prognostic Factors of Resected Salivary Gland Malignancies: Examining a Single Institution’s 12-Year Experience. Anticancer Res. 2017, 37, 5019–5025. [Google Scholar] [PubMed]
- Sayan, M.; Vempati, P.; Miles, B.; Teng, M.; Genden, E.; Demicco, E.G.; Misiukiewicz, K.; Posner, M.; Gupta, V.; Bakst, R.L. Adjuvant Therapy for Salivary Gland Carcinomas. Anticancer Res. 2016, 36, 4165–4170. [Google Scholar] [PubMed]
- Mifsud, M.J.; Tanvetyanon, T.; McCaffrey, J.C.; Otto, K.J.; Padhya, T.A.; Kish, J.; Trotti, A.M.; Harrison, L.B.; Caudell, J.J. Adjuvant Radiotherapy Versus Concurrent Chemoradiotherapy for the Management of High-Risk Salivary Gland Carcinomas. Head Neck 2016, 38, 1628–1633. [Google Scholar] [CrossRef]
- Hosni, A.; Huang, S.H.; Goldstein, D.; Xu, W.; Chan, B.; Hansen, A.; Weinreb, I.; Bratman, S.V.; Cho, J.; Giuliani, M.; et al. Outcomes and Prognostic Factors for Major Salivary Gland Carcinoma Following Postoperative Radiotherapy. Oral Oncol. 2016, 54, 75–80. [Google Scholar] [CrossRef]
- Haderlein, M.; Scherl, C.; Semrau, S.; Lettmaier, S.; Uter, W.; Neukam, F.W.; Iro, H.; Agaimy, A.; Fietkau, R. High-Grade Histology as Predictor of Early Distant Metastases and Decreased Disease-Free Survival in Salivary Gland Cancer Irrespective of Tumor Subtype. Head Neck 2016, 38 (Suppl. S1), E2041–E2048. [Google Scholar] [CrossRef] [PubMed]
- Kaur, J.; Goyal, S.; Muzumder, S.; Bhasker, S.; Mohanti, B.K.; Rath, G.K. Outcome of Surgery and Post-Operative Radiotherapy for Major Salivary Gland Carcinoma: Ten Year Experience from a Single Institute. Asian Pac. J. Cancer Prev. 2014, 15, 8259–8263. [Google Scholar] [CrossRef] [PubMed]
- Tam, M.; Riaz, N.; Salgado, L.R.; Spratt, D.E.; Katsoulakis, E.; Ho, A.; Morris, L.G.T.; Wong, R.; Wolden, S.; Rao, S.; et al. Distant Metastasis Is a Critical Mode of Failure for Patients with Localized Major Salivary Gland Tumors Treated with Surgery and Radiation. J. Radiat. Oncol. 2013, 2, 285–291. [Google Scholar] [CrossRef] [PubMed]
- Chung, M.P.; Tang, C.; Chan, C.; Hara, W.Y.; Loo, B.W., Jr.; Kaplan, M.J.; Fischbein, N.; Le, Q.T.; Chang, D.T. Radiotherapy for Nonadenoid Cystic Carcinomas of Major Salivary Glands. Am. J. Otolaryngol. 2013, 34, 425–430. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.Y.; Lee, S.; Cho, K.J.; Kim, S.Y.; Nam, S.Y.; Choi, S.H.; Roh, J.L.; Choi, E.K.; Kim, J.H.; Song, S.Y.; et al. Treatment Results of Post-Operative Radiotherapy in Patients with Salivary Duct Carcinoma of the Major Salivary Glands. Br. J. Radiol. 2012, 85, e947–e952. [Google Scholar] [CrossRef] [PubMed]
- Al-Mamgani, A.; van Rooij, P.; Verduijn, G.M.; Meeuwis, C.A.; Levendag, P.C. Long-Term Outcomes and Quality of Life of 186 Patients with Primary Parotid Carcinoma Treated with Surgery and Radiotherapy at the Daniel Den Hoed Cancer Center. Int. J. Radiat. Oncol. Biol. Phys. 2012, 84, 189–195. [Google Scholar] [CrossRef] [PubMed]
- Pederson, A.W.; Salama, J.K.; Haraf, D.J.; Witt, M.E.; Stenson, K.M.; Portugal, L.; Seiwert, T.; Villaflor, V.M.; Cohen, E.E.; Vokes, E.E.; et al. Adjuvant Chemoradiotherapy for Locoregionally Advanced and High-Risk Salivary Gland Malignancies. Head Neck Oncol. 2011, 3, 31. [Google Scholar] [CrossRef] [PubMed]
- Noh, J.M.; Ahn, Y.C.; Nam, H.; Park, W.; Baek, C.H.; Son, Y.I.; Jeong, H.S. Treatment Results of Major Salivary Gland Cancer by Surgery with or without Postoperative Radiation Therapy. Clin. Exp. Otorhinolaryngol. 2010, 3, 96–101. [Google Scholar] [CrossRef] [PubMed]
- Chen, A.M.; Garcia, J.; Lee, N.Y.; Bucci, M.K.; Eisele, D.W. Patterns of Nodal Relapse after Surgery and Postoperative Radiation Therapy for Carcinomas of the Major and Minor Salivary Glands: What Is the Role of Elective Neck Irradiation? Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 988–994. [Google Scholar] [CrossRef]
- Safdieh, J.; Givi, B.; Osborn, V.; Lederman, A.; Schwartz, D.; Schreiber, D. Impact of Adjuvant Radiotherapy for Malignant Salivary Gland Tumors. Otolaryngol. Head Neck Surg. 2017, 157, 988–994. [Google Scholar] [CrossRef]
- Aro, K.; Ho, A.S.; Luu, M.; Kim, S.; Tighiouart, M.; Yoshida, E.J.; Clair, J.M.-S.; Shiao, S.L.; Leivo, I.; Zumsteg, Z.S. Survival Impact of Adjuvant Therapy in Salivary Gland Cancers Following Resection and Neck Dissection. Otolaryngol. Head Neck Surg. 2019, 160, 1048–1057. [Google Scholar] [CrossRef]
- Ferrell, J.K.; Mace, J.C.; Clayburgh, D. Contemporary Treatment Patterns and Outcomes of Salivary Gland Carcinoma: A National Cancer Database Review. Eur. Arch. Otorhinolaryngol. 2019, 276, 1135–1146. [Google Scholar] [CrossRef]
- North, L.; Stadler, M.; Massey, B.; Campbell, B.; Shukla, M.; Awan, M.; Schultz, C.J.; Shreenivas, A.; Wong, S.; Graboyes, E.; et al. Intermediate-Grade Carcinoma of the Parotid and the Impact of Adjuvant Radiation. Am. J. Otolaryngol. 2019, 40, 102282. [Google Scholar] [CrossRef]
- Morand, G.B.; Eskander, A.; Fu, R.; de Almeida, J.; Goldstein, D.; Noroozi, H.; Hosni, A.; Seikaly, H.; Tabet, P.; Pyne, J.M.; et al. The Protective Role of Postoperative Radiation Therapy in Low and Intermediate Grade Major Salivary Gland Malignancies: A Study of the Canadian Head and Neck Collaborative Research Initiative. Cancer 2023, 129, 3263–3274. [Google Scholar] [CrossRef]
- Hong, W.J.; Chang, S.L.; Tsai, C.J.; Wu, H.C.; Chen, Y.C.; Yang, C.C.; Ho, C.H. The Effect of Adjuvant Radiotherapy on Clinical Outcomes in Early Major Salivary Gland Cancer. Head Neck 2022, 44, 2865–2874. [Google Scholar] [CrossRef]
- Amini, A.; Waxweiler, T.V.; Brower, J.V.; Jones, B.L.; McDermott, J.D.; Raben, D.; Ghosh, D.; Bowles, D.W.; Karam, S.D. Association of Adjuvant Chemoradiotherapy vs. Radiotherapy Alone with Survival in Patients with Resected Major Salivary Gland Carcinoma: Data from the National Cancer Data Base. JAMA Otolaryngol. Head Neck Surg. 2016, 142, 1100–1110. [Google Scholar] [CrossRef]
- Cheraghlou, S.; Kuo, P.; Mehra, S.; Agogo, G.O.; Bhatia, A.; Husain, Z.A.; Yarbrough, W.G.; Burtness, B.A.; Judson, B.L. Adjuvant Therapy in Major Salivary Gland Cancers: Analysis of 8580 Patients in the National Cancer Database. Head Neck 2018, 40, 1343–1355. [Google Scholar] [CrossRef]
- Tanvetyanon, T.; Fisher, K.; Caudell, J.; Otto, K.; Padhya, T.; Trotti, A. Adjuvant Chemoradiotherapy Versus with Radiotherapy Alone for Locally Advanced Salivary Gland Carcinoma among Older Patients. Head Neck 2016, 38, 863–870. [Google Scholar] [CrossRef]
- Dennis, K.; Linden, K.; Gaudet, M. A Shift from Simple to Sophisticated: Using Intensity-Modulated Radiation Therapy in Conventional Nonstereotactic Palliative Radiotherapy. Curr. Opin. Support. Palliat. Care 2023, 17, 70–76. [Google Scholar] [CrossRef]
- Kim, E.; Jang, W.I.; Yang, K.; Kim, M.S.; Yoo, H.J.; Paik, E.K.; Kim, H.; Yoon, J. Clinical Utilization of Radiation Therapy in Korea between 2017 and 2019. Radiat. Oncol. J. 2022, 40, 251–259. [Google Scholar] [CrossRef]
- Jang, W.I.; Jo, S.; Moon, J.E.; Bae, S.H.; Park, H.C. The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers 2023, 15, 4914. [Google Scholar] [CrossRef]
- Kong, L.; Lu, J.J.; Liss, A.L.; Hu, C.; Guo, X.; Wu, Y.; Zhang, Y. Radiation-Induced Cranial Nerve Palsy: A Cross-Sectional Study of Nasopharyngeal Cancer Patients after Definitive Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79, 1421–1427. [Google Scholar] [CrossRef]
- Rong, X.; Tang, Y.; Chen, M.; Lu, K.; Peng, Y. Radiation-Induced Cranial Neuropathy in Patients with Nasopharyngeal Carcinoma. A Follow-up Study. Strahlenther. Onkol. 2012, 188, 282–286. [Google Scholar] [CrossRef]
- Luk, Y.S.; Shum, J.S.; Sze, H.C.; Chan, L.L.; Ng, W.T.; Lee, A.W. Predictive Factors and Radiological Features of Radiation-Induced Cranial Nerve Palsy in Patients with Nasopharyngeal Carcinoma following Radical Radiotherapy. Oral Oncol. 2013, 49, 49–54. [Google Scholar] [CrossRef]
- Blettner, M.; Sauerbrei, W.; Schlehofer, B.; Scheuchenpflug, T.; Friedenreich, C. Traditional Reviews, Meta-Analyses and Pooled Analyses in Epidemiology. Int. J. Epidemiol. 1999, 28, 1–9. [Google Scholar] [CrossRef]
- Beller, E.M.; Chen, J.K.; Wang, U.L.; Glasziou, P.P. Are Systematic Reviews up-to-Date at the Time of Publication? Syst. Rev. 2013, 2, 36. [Google Scholar] [CrossRef]
Author | pTstage: 1/2/3/4(%) | pNstage: 0/1/2/3(%) | LVI (%) | PNI (%) | Median f/u (mo) | 3-yr LRC (%) | 5-yr LRC (%) | 10-yr LRC (%) | 3-yr DMFS (%) | 5-yr DMFS (%) | 10-yr DMFS (%) | 3-yr DFS (%) | 5-yr DFS (%) | 10-yr DFS (%) | 3-yr OS (%) | 5-yr OS (%) | 10-yr OS (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Yan [17] | 28/48/11/13 | 67/13/17/3 | 8 | 26 | 60 | - | - | - | 79 | 72 | 59 | - | - | - | 90 | 81 | 63 |
Park [18] | 30/30/32/8 | 100/0/0/0 | 16 | 20 | - | 99 | 95 | - | - | - | - | 95 | 86 | - | - | - | - |
Duru Birgi [19] | 22/45/11/0 | 56/11/11/0 | 0 | 11 | 30 | - | - | - | - | - | - | - | - | - | - | - | - |
Hsieh_A [20] | 30/33/19/18 | 85/3/12/0 | 13 | 39 | 131 c | 92 | 89 | 85 | - | - | - | 78 | 72 | 64 | 88 | 80 | 72 |
Hsieh_B [20] | 13/36/24/27 | 58/9/33/0 | 20 | 49 | 131 c | 87 | 83 | 82 | - | - | - | 66 | 59 | 53 | 80 | 71 | 61 |
Zang [21] | 23/7 a | 68/13/19/0 | - | 32 | 56 | 87 | 82 | 82 | 85 | 78 | 66 | 80 | 73 | 63 | 91 | 85 | 85 |
Franco [22] | - | - | - | - | 41 | - | - | - | - | - | - | - | - | - | - | - | - |
Dou [23] | - | - | - | - | 16 | - | - | - | - | - | - | - | - | - | - | - | - |
Nutting_A [24] | 30/28/13/22 | 59/7/26/0 | - | - | 50 c | - | - | - | - | - | - | 81 | - | - | 81 | - | - |
Nutting_B [24] | 29/39/14/16 | 66/13/16/0 | - | - | 50 c | - | - | - | - | - | - | 81 | - | - | 86 | - | - |
Nishikado [25] | - | - | - | - | - | - | - | - | - | - | - | - | 53 | - | - | - | - |
Li [26] | - | - | - | 10 | 21 | 88 | - | - | 95 | - | - | - | - | - | - | - | - |
Gebhardt [27] | 31/31/16/22 | 70/5/25/0 | 37 | 53 | 54 | - | 86 | - | - | 77 | - | - | 61 | - | - | 73.7 | - |
Boon [28] | 47/47/0/0 | 93/0/7/0 | - | - | - | - | - | - | - | - | - | 100 | 89 | 89 | 100 | 89 | 89 |
Zhang [29] | - | - | - | - | - | 92 d | 87 d | - | - | - | - | 93 | 88 | - | 87 | 82 | - |
Gutschenritter [30] | - | - | - | - | - | - | - | - | - | - | - | 70 | 58 | - | 79 | 68 | - |
Sayan [31] | 35/25/40/0 | 90/10/0/0 | - | 25 | 37 | 96 | - | - | - | - | - | 90 | - | - | 100 | - | - |
Mifsud_A [32] | 32/23/23/22 | 80/6/14/0 | 21 | 53 | 35 c | 91 | - | - | 83 | - | - | 74 | 60 | - | 78 | - | - |
Mifsud_B [32] | 16/14/30/40 | 35/14/51/0 | 38 | 84 | 35 c | 79 | - | - | 53 | - | - | 42 | 27 | - | 52 | - | - |
Hosni [33] | 63/37 a | 73/9/18/0 | 22 | 53 | 82 | 97 d | 96 d | 96 d | 84 | 80 | 77 | - | - | - | 84 | 78 | 75 |
Haderlein [34] | 24/15/44/14 | 49/22/29/0 | - | 60 | 31 | 86 | 86 | - | - | 62 | - | - | 58 | - | - | 63 | - |
Kaur [35] | - | - | - | - | 11 | - | - | - | - | - | - | 49 | - | - | - | - | - |
Tam [36] | 31/33/19/15 | 65/14/18/0 | - | - | 50 | 91 d | 88 d | - | 81 | 73 | - | - | - | - | 85 | 77 | 59 |
Chung [37] | 14/30/16/40 | 51/49 b | - | - | 56 | 97 | 97 | - | - | - | - | - | - | - | 77 | 76 | - |
Kim [38] | 17/31/43/9 | 26/74 b | 51 | 34 | 43 | 77 | 63 | 63 | - | - | - | 56 | 47 | 47 | - | 55 | - |
Al-Mamgani [39] | 27/49/16/8 | 80/6/13/1 | - | - | 58 | 92 | 89 | - | - | - | - | 83 | 83 | - | 72 | 68 | - |
Pederson [40] | 4/34/25/37 | 25/13/62/0 | - | 54 | 42 | 96 | 96 | - | - | - | - | 62 | 55 | - | 79 | 59 | - |
Noh [41] | 21/28/35/16 | 81/7/12/0 | 16 | 19 | - | - | 96 | - | - | - | - | - | 74 | - | - | 78 | - |
Chen [42] | 17/33/27/24 | - | - | 74 | 62 | - | - | - | - | - | - | - | 81 | 63 | 96 | 81 | 57 |
Group | Cohorts (n) | Patients (n) | p, Heterogeneity | I2 | Egger’s Test, p | Fixed Event Rate (95% CI) | Random Event Rate (95% CI) | p (between Groups) |
---|---|---|---|---|---|---|---|---|
3-year LRC | ||||||||
All | 16 | 1648 | <0.0001 | 71.09% | 0.1752 | 0.93 (0.92–0.94) | 0.92 (0.89–0.94) | |
Post-op CCRT a | 4 | 229 | 0.2824 | 21.32% | 0.8796 | 0.88 (0.83–0.92) | 0.88 (0.82–0.93) | 0.0875 |
PORT b | 4 | 416 | 0.9845 | 0% | 0.7215 | 0.93 (0.90–0.95) | 0.93 (0.90–0.95) | |
High grade > 50% c | 6 | 570 | 0.0313 | 59.25% | 0.2016 | 0.89 (0.86–0.92) | 0.87 (0.82–0.92) | 0.0150 |
High grade ≤ 50% | 5 | 731 | 0.0025 | 75.63% | 0.5867 | 0.96 (0.94–0.97) | 0.95 (0.91–0.98) | |
mRT dose > 64 Gy | 5 | 682 | 0.0035 | 74.52% | 0.5371 | 0.94 (0.92–0.96) | 0.93 (0.88–0.97) | 0.5628 |
mRT dose ≤ 64 Gy | 10 | 936 | <0.0001 | 73.85% | 0.3466 | 0.92 (0.90–0.94) | 0.91 (0.87–0.95) | |
5-year LRC | ||||||||
All | 14 | 1671 | <0.0001 | 77.99% | 0.3034 | 0.90 (0.89–0.92) | 0.89 (0.86–0.93) | |
Post-op CCRT | 2 | 172 | 0.0943 | 64.28% | - | 0.86 (0.80–0.91) | 0.89 (0.75–0.98) | 0.6259 |
PORT | 3 | 368 | 0.1140 | 53.95% | 0.8597 | 0.91 (0.88–0.94) | 0.91 (0.85–0.96) | |
High grade > 50% | 6 | 608 | 0.0003 | 78.75% | 0.7549 | 0.88 (0.85–0.90) | 0.87 (0.80–0.93) | 0.1827 |
High grade ≤ 50% | 4 | 736 | 0.0009 | 81.73% | 0.3854 | 0.93 (0.91–0.95) | 0.92 (0.87–0.96) | |
mRT dose > 64 Gy | 5 | 790 | <0.0001 | 84.57% | 0.5832 | 0.91 (0.89–0.93) | 0.90 (0.84–0.95) | 0.7043 |
mRT dose ≤ 64 Gy | 8 | 851 | <0.0001 | 77.55% | 0.6316 | 0.90 (0.87–0.92) | 0.89 (0.84–0.93) | |
10-year LRC | ||||||||
All | 5 | 810 | <0.0001 | 91.93% | 0.1546 | 0.89 (0.86–0.91) | 0.84 (0.73–0.92) | |
Post-op CCRT | 1 | 148 | - | - | - | 0.82 (0.75–0.88) | 0.82 (0.75–0.88) | 0.3608 |
PORT | 1 | 263 | - | - | - | 0.85 (0.81–0.89) | 0.85 (0.81–0.89) | |
High grade > 50% | 3 | 446 | 0.0130 | 76.96% | 0.0151 | 0.83 (0.79–0.86) | 0.80 (0.70–0.88) | <0.0001 |
High grade ≤ 50% | 1 | 304 | - | - | - | 0.96 (0.94–0.98) | 0.96 (0.94–0.98) | |
mRT dose > 64 Gy | 2 | 452 | <0.0001 | 95.66% | - | 0.92 (0.90–0.95) | 0.90 (0.72–0.99) | 0.2421 |
mRT dose ≤ 64 Gy | 3 | 358 | 0.0131 | 76.92% | 0.3025 | 0.83 (0.79–0.87) | 0.79 (0.66–0.89) | |
3-year DFS | ||||||||
All | 16 | 1266 | <0.0001 | 85.97% | 0.6650 | 0.78 (0.76–0.80) | 0.77 (0.70–0.83) | |
Post-op CCRT | 3 | 209 | 0.0421 | 68.44% | 0.5343 | 0.62 (0.55–0.69) | 0.58 (0.43–0.73) | 0.0090 |
PORT | 9 | 658 | <0.0001 | 76.08% | 0.4283 | 0.78 (0.74–0.81) | 0.80 (0.72–0.86) | |
High grade > 50% | 5 | 507 | <0.0001 | 83.26% | 0.0811 | 0.70 (0.66–0.74) | 0.63 (0.51–0.75) | 0.0054 |
High grade ≤ 50% | 5 | 517 | 0.0001 | 82.42% | 0.7517 | 0.84 (0.81–0.87) | 0.84 (0.75–0.91) | |
mRT dose > 64 Gy | 6 | 483 | 0.0002 | 79.55% | 0.6255 | 0.78 (0.74–0.82) | 0.80 (0.70–0.88) | 0.4020 |
mRT dose ≤ 64 Gy | 8 | 675 | <0.0001 | 90.67% | 0.3045 | 0.78 (0.75–0.81) | 0.73 (0.60–0.84) | |
5-year DFS | ||||||||
All | 17 | 1672 | <0.0001 | 87.62% | 0.1034 | 0.71 (0.68–0.73) | 0.67 (0.60–0.74) | |
Post-op CCRT | 3 | 209 | 0.0022 | 83.69% | 0.5542 | 0.53 (0.46–0.59) | 0.47 (0.27–0.67) | 0.0522 |
PORT | 7 | 622 | 0.0008 | 73.74% | 0.8001 | 0.68 (0.65–0.72) | 0.69 (0.61–0.77) | |
High grade > 50% | 7 | 645 | <0.0001 | 84.82% | 0.0866 | 0.64 (0.60–0.67) | 0.58 (0.46–0.68) | 0.0780 |
High grade ≤ 50% | 4 | 535 | <0.0001 | 91.90% | 0.4448 | 0.75 (0.71–0.78) | 0.73 (0.59–0.85) | |
mRT dose > 64 Gy | 5 | 501 | <0.0001 | 88.32% | 0.8474 | 0.70 (0.66–0.74) | 0.69 (0.55–0.81) | 0.6700 |
mRT dose ≤ 64 Gy | 10 | 1063 | <0.0001 | 89.39% | 0.0252 | 0.71 (0.68–0.74) | 0.65 (0.55–0.74) | |
10-year DFS | ||||||||
All | 6 | 772 | 0.0307 | 59.39% | 0.8729 | 0.61 (0.58–0.65) | 0.61 (0.55–0.67) | |
Post-op CCRT | 1 | 148 | - | - | - | 0.53 (0.45–0.61) | 0.53 (0.45–0.61) | 0.1010 |
PORT | 2 | 278 | 0.0655 | 70.53% | - | 0.66 (0.60–0.71) | 0.73 (0.50–0.91) | |
High grade > 50% | 3 | 446 | 0.0379 | 69.44% | 0.4465 | 0.59 (0.54–0.64) | 0.57 (0.47–0.66) | - |
High grade ≤ 50% | 0 | 0 | - | - | - | - | ||
mRT dose > 64 Gy | 2 | 163 | 0.0080 | 85.78% | - | 0.56 (0.48–0.64) | 0.69 (0.34–0.95) | 0.7471 |
mRT dose ≤ 64 Gy | 4 | 609 | 0.3888 | 0.61% | 0.2291 | 0.63 (0.59–0.67) | 0.63 (0.59–0.67) | |
3-year OS | ||||||||
All | 18 | 2284 | <0.0001 | 84.23% | 0.8229 | 0.84 (0.83–0.86) | 0.84 (0.79–0.88) | |
Post-op CCRT | 3 | 209 | 0.0038 | 82.04% | 0.6017 | 0.75 (0.69–0.81) | 0.71 (0.52–0.87) | 0.0755 |
PORT | 8 | 619 | 0.0070 | 63.94% | 0.4503 | 0.86 (0.83–0.89) | 0.87 (0.81–0.92) | |
High grade > 50% | 4 | 472 | <0.0001 | 87.60% | 0.2295 | 0.83 (0.79–0.86) | 0.77 (0.63–0.88) | 0.5862 |
High grade ≤ 50% | 6 | 1121 | 0.0481 | 55.24% | 0.8811 | 0.80 (0.78–0.83) | 0.80 (0.76–0.84) | |
mRT dose > 64 Gy | 7 | 787 | 0.0071 | 66.03% | 0.4498 | 0.81 (0.78–0.84) | 0.82 (0.76–0.87) | 0.4812 |
mRT dose ≤ 64 Gy | 8 | 971 | <0.0001 | 89.66% | 0.3286 | 0.88 (0.86–0.90) | 0.85 (0.77–0.92) | |
5-year OS | ||||||||
All | 17 | 2315 | 0.0001 | 64.47% | 0.0875 | 0.77 (0.75–0.79) | 0.75 (0.72–0.79) | |
Post-op CCRT | 2 | 172 | 0.2185 | 33.97% | - | 0.70 (0.62–0.76) | 0.68 (0.56–0.78) | 0.0903 |
PORT | 5 | 461 | 0.2404 | 27.17% | 0.9974 | 0.79 (0.75–0.82) | 0.78 (0.73–0.83) | |
High grade > 50% | 6 | 608 | 0.0021 | 73.40% | 0.0424 | 0.74 (0.70–0.78) | 0.70 (0.62–0.78) | 0.2397 |
High grade ≤ 50% | 4 | 1036 | 0.0030 | 78.45% | 0.1743 | 0.77 (0.75–0.80) | 0.76 (0.70–0.81) | |
mRT dose > 64 Gy | 6 | 805 | 0.0615 | 52.52% | 0.6291 | 0.74 (0.70–0.77) | 0.73 (0.68–0.78) | 0.3252 |
mRT dose ≤ 64 Gy | 8 | 984 | 0.0063 | 64.42% | 0.1360 | 0.78 (0.75–0.81) | 0.76 (0.71–0.81) | |
10-year OS | ||||||||
All | 8 | 1659 | <0.0001 | 85.03% | 0.3694 | 0.67 (0.64–0.69) | 0.68 (0.62–0.74) | |
Post-op CCRT | 1 | 148 | - | - | - | 0.61 (0.53–0.69) | 0.61 (0.53–0.69) | 0.0453 |
PORT | 2 | 278 | 0.2472 | 25.32% | - | 0.74 (0.68–0.79) | 0.75 (0.65–0.85) | |
High grade > 50% | 2 | 411 | 0.0257 | 79.91% | - | 0.68 (0.64–0.73) | 0.67 (0.56–0.77) | 0.8249 |
High grade ≤ 50% | 2 | 722 | 0.0005 | 91.67% | 0.68 (0.65–0.72) | 0.69 (0.57–0.80) | ||
mRT dose > 64 Gy | 3 | 467 | 0.0062 | 80.33% | 0.9409 | 0.72 (0.67–0.76) | 0.72 (0.60–0.83) | 0.6456 |
mRT dose ≤ 64 Gy | 4 | 774 | <0.0001 | 89.58% | 0.4103 | 0.65 (0.62–0.69) | 0.68 (0.57–0.78) |
Author | Criteria | Overall Toxicity (%) | Severe Toxicity (%) |
---|---|---|---|
Park [18] | CTCAEv5.0 | Hearing loss of Gr3 (1) | Gr3 (1) |
Duru Birgi [19] | CTCAEv4.0 | Trigeminal nerve toxicity of Gr1 (22) and Gr2 (39) | No ≥ Gr3 toxicity |
Zang [21] | - | Xerostomia (30); Hearing impairment (28); Taste abnormalities (25); Paresthesia (23); Fibrosis of the skin (18); Trismus (10); ORN (3) | Gr3 (3) |
Nutting_A [24] | CTCAEv3.0 | Hearing toxicity of Gr1 (31), Gr2 (29), Gr3 (12), and Gr4 (2); OE of Gr1 (26), Gr2 (6), and Gr3 (2); OM of Gr1 (28), Gr2 (4), and Gr3 (2); Tinnitus of Gr2 (56) and Gr3 (2); Otalgia of Gr1 (24), Gr2 (10), and Gr3 (2); Skin pigmentation of Gr1 (49) and Gr 2 (6); Skin atrophy of Gr1 (48) and Gr2 (2); Skin fibrosis of Gr1 (52) and Gr2 (10); Functional mucous membrane toxicity of Gr1(20), Gr2 (8), and Gr3 (2); Clinical exam-mucous membrane toxicity of Gr1 (24) and Gr2 (4); Dry mouth of Gr1 (58), Gr2 (22), and Gr3 (4); Salivary gland changes of Gr1 (54) and Gr2 (20); ORN of Gr1 (2); Trismus of Gr1 (30) and Gr2 (6); Fatigue of Gr1 (26), Gr2 (10), and Gr3 (6) | Gr3 (32)/Gr4 (2) |
Nutting_B [24] | CTCAEv3.0 | Hearing toxicity of Gr1 (37), Gr2 (20), Gr3 (9), and Gr4 (7); OE of Gr1 (30) and Gr2 (7); OM of Gr1 (30) and Gr2 (4); Tinnitus of Gr1 (4), Gr2 (37), and Gr3 (7); Otalgia of Gr1 (28) and Gr2 (2); Skin pigmentation of Gr1 (43) and Gr 2 (4); Skin atrophy of Gr1 (44) and Gr2 (2); Skin fibrosis of Gr1 (56) and Gr2 (4); Functional mucous membrane toxicity of Gr1 (33) and Gr2 (9); Clinical exam-mucous membrane toxicity of Gr1 (24) and Gr2 (4); Dry mouth of Gr1 (72), Gr2 (20), and Gr3 (2)/Salivary gland changes of Gr1 (69), Gr2 (7), and Gr3 (2); ORN of Gr1 (2); Trismus of Gr1 (43) and Gr2 (6); Fatigue of Gr1 (40) and Gr2 (8) | Gr3 (20)/Gr4 (7) |
Gebhardt [27] | CTCAEv4.0 | Gr1 (52) and Gr2 (13) | No ≥ Gr3 toxicity |
Sayan [31] | RTOG/EORTC | Xerostomia of Gr2 (25); Hearing loss (5) | Gr3 (5) |
Hosni [33] | RTOG | ORN of Gr3 (1); Neck fibrosis of Gr3 (1); Trismus of Gr3 (0.3); Dysphagia of Gr3 (0.3) | Gr3 (3) |
Tam [36] | CTCAEv4.0 | Xerostomia of Gr 1–2 (54) and Gr 3 (1); Hearing loss of Gr 1–3 (19); PEG replacement (2); Radiation necrosis of Gr1 (1) | Gr3 (19) |
Chung [37] | CTCAEv4.0 | Hypothyroidism of Gr2, Xerostomia of Gr2, Trismus of Gr2; Fibrosis of Gr3 in 1 patient (3) | Gr3 (3) |
Al-Mamgani [39] | CTCAEv3.0 | Overall toxicities ≥ Gr2 (8); ORN of Gr3 (2); Hearing loss requiring hearing aid (6); Dysphagia and xerostomia of Gr2 (2); Subcutaneous toxicities of Gr2 (2) | Gr3 (9) |
Pederson [40] | CTCAEv3.0 | Xerostomia (21)/Esophageal stricture requiring dilatation (4)/TMJ syndrome (4)/Feeding tubes (13) | Gr3 (21) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, J.; Moon, J.E.; Guo, X.; Yu, J.; Yi, J.; Bae, S.H. The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis. Cancers 2024, 16, 2375. https://doi.org/10.3390/cancers16132375
Wang J, Moon JE, Guo X, Yu J, Yi J, Bae SH. The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis. Cancers. 2024; 16(13):2375. https://doi.org/10.3390/cancers16132375
Chicago/Turabian StyleWang, Jingbo, Ji Eun Moon, Xin Guo, Jiaqi Yu, Junlin Yi, and Sun Hyun Bae. 2024. "The Current Position of Postoperative Radiotherapy for Salivary Gland Cancer: A Systematic Review and Meta-Analysis" Cancers 16, no. 13: 2375. https://doi.org/10.3390/cancers16132375